Our content partners

Together with Immunexpress we focus on the development and commercialization of SeptiCyte® RAPID on the Idylla™ Platform.  SeptiCyte® RAPID is a rapid host-response gene expression signature test that distinguishes sepsis from non-infectious systemic inflammation (INSI/SIRS). It provides actionable results in about one hour enabling physicians to optimize their patient management decisions.

Together with GeneproDX we focus on the development and commercialization of ThyroidPrint® for use on the Idylla™ Platform. ThyroidPrint® is a gene expression signature (GEP) test that can identify patients with indeterminate thyroid FNA (fine needle aspiration biopsy) that can safely forego thyroid surgery.

Together with Endpoint Health we focus on the development and commercialization of the Endpoint Health test for use on the Idylla™ Platform. The Endpoint Health test is a gene expression signature test that can direct therapeutic decisions in critically ill patients, such as sepsis patients.

Together with SkylineDx we focus on the development and commercialization of the Merlin™ Assay. The Merlin Assay is a gene expression signature that, in combination with clinical and pathological parameters, helps identifying melanoma patients with intermediate thickness primary melanoma that can safely forego a sentinel lymph node surgery.

Together with Ophiomics we focus on the commercialization of HepatoPredict™, a prognostic gene expression signature test that can help identify which liver cancer patients will benefit from curative-intent surgery, in particular liver transplantation.

Together with HiloProbe we focus on the commercialization of the ColoNode^® CE-marked IVD manual kit in selected European countries by Biocartis.

Together with APIS Technology Assays we focus on the development of the APIS Breast Cancer Subtyping Assay on Biocartis’ rapid and easy-to-use molecular diagnostics platform Idylla™.